Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELDN | US
-0.23
-6.12%
Healthcare
Biotechnology
30/06/2024
02/06/2026
3.53
3.73
3.73
3.53
Eledon Pharmaceuticals Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart an anti-CD40L antibody with high affinity for CD40 Ligand a biological target with therapeutic potential. It has a collaboration agreement with eGenesis Inc. The company was formerly known as Novus Therapeutics Inc. and changed its name to Eledon Pharmaceuticals Inc. in January 2021. Eledon Pharmaceuticals Inc. is headquartered in Irvine California.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.0%1 month
45.4%3 months
69.2%6 months
66.1%6.60
5.39
1.31
-0.08
0.01
0.84
-
-
-36.86M
146.08M
146.08M
-
-
-
-
-70.71
1.57
0.36
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.63
Range1M
0.73
Range3M
1.78
Rel. volume
0.86
Price X volume
3.31M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 4.92 | 158.16M | -2.19% | n/a | -2.87% |
| Assembly Biosciences Inc | ASMB | Biotechnology | 24.49 | 155.40M | -9.03% | n/a | 5.03% |
| Verastem Inc | VSTM | Biotechnology | 3.81 | 153.33M | -9.07% | n/a | 104.63% |
| Spero Therapeutics Inc | SPRO | Biotechnology | 2.83 | 152.96M | 0.00% | 3.76 | 6.13% |
| Galectin Therapeutics Inc | GALT | Drug Manufacturers-Specialty & Generic | 2.42 | 150.71M | -7.28% | n/a | -113.78% |
| Adagene Inc. | ADAG | Biotechnology | 3.39 | 150.08M | -10.32% | n/a | 36.29% |
| Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 4.51 | 149.11M | -6.24% | n/a | 6.58% |
| MediWound Ltd | MDWD | Biotechnology | 13.76 | 148.42M | -0.43% | n/a | 0.00% |
| OBIO | OBIO | Biotechnology | 3.91 | 147.89M | 2.09% | n/a | 3.29% |
| Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 3.6 | 146.77M | -7.46% | 4.54 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.84 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | 6.60 | 41.03 | Cheaper |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 69.19 | - | Par |
| Debt to Equity | -0.08 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 146.08M | - | Emerging |